PYX Resources: Achieving volume and diversification milestones. Watch the video here.
Hi Botak, Happy New Year to you. Very positive podcast and something of a rerating afoot? As profit says below we do need the BOD to engage in news flow this year. Waiting 6 months between results does not get the message to the market....so make investor relations a vital component of valuing the company properly. Be very interesting to see the level of clinical sales of TexRAD this year and roll-out of other incarnations, that could easily make FDBK a multi bagger this year imo.
Morning all, let us hope that the New Year delivers TexRAD in abundance to clinicians around the world. My hope would be: FDBK to move into profitability TexRAD Lung to be followed by Liver with others on the horizon Sp to be north of 10p as profits mushroom JV,s announced that show TexRAD will benefit patients across the World BOD communicating with shareholders regularly and meaningful announcements accompanying results. I wish you all a prosperous and above all healthy New Year.
Evening El, hope you had a good Christmas with the grandkids. Interesting move by Mr Cranston you don’t do that without considerable confidence. I do not recall seeing a trade of 2m go through so I guess he made a few buys when the sp was earlier suppressed?. Could our BOD be about to make a significant announcement or is the sp being gently rerated towards a more realistic valuation (tho still some way short imo)? GLA lths and a very Happy New Year to all FDBK followers in 2018.
Afternoon Hors, my very best wishes to you and your family enjoy the holidays as the FDBK market draws to a close....at a lower point than a year ago despite CE! Not sure of my New Year resolution regarding FDBK but I will try to be positive and hope to receive encouragement in that regard from the Company. To all lth’s esp El, Botak,IF and adrianz I send you seasons greetings, enjoy your time with family and friends and let us hope as hors says that many clinicians are able to benefit their patients by using TexRAD in 2018. All from me until the New Year...
Agree with all that adrianz, but the jury is certainly out on AR. His cv reads very well but it is all with established Companies with strong market presence there is no record of bringing a fledgling company with potentially leading product to be a market force. It does concern me that he lacks the driving force to do this, and why oh why has he not bought any shares since he was gifted 5m at outset does he not believe in the products success? Many questions remain about AR.
Afternoon El, hope you are well. That’s a high price for TB to pay for petulance, think there must be more to it than that. What do you make of the 3 x 2.5m trades yesterday? Since the CE we have heard nothing from FDBK, goodness knows what the sales team are up to. Communication is a disgrace, mind you we don’t need another AR unfulfilled promise....will Liver get a CE mark by April? 2018 cannot be as frustrating as this year....on that note a Merry Christmas and Prosperous New Year to all Holders.
Agree adrianz and Botak but what about accountability? I am fortunate not to be in need of the money but like all investors I expect a decent return, my interest here was ethical due to the nature of the product and it’s ability to help in the detection of terrible diseases. That TexRAD is not setting the world alight despite the clear advantages it affords should be a real concern to those engaged in mismanaging it’s commercialisation. IMHO AR has been a disaster, gifted shares upon appointment he has not felt the need to invest in any further shares in his company despite the appalling sp performance (no note of Director dealings to suggest otherwise) and this lack of personal interest sums up his lack of direction imo. I would happily detract this if proven otherwise but the apparent disdain shown to shareholders via erroneous information, lack of communication, opaque prospects etc is awful for a supposedly ethical product. Let GE takeover for a paltry 5p and at least commercialise TexRAD properly.
Absolutely farcical, FDBK is now worth we’ll under half what it was pre-CE Mark! Come on BOD you have to take some responsibility for the total lack of market interest in your Company.....performance last 3 months has been pathetic. I seriously question whether you are up to the job of delivering the commercial success that TexRAD deserves: what are current sales plans (have and deals produced income?), what are performance targets for this half-year?, is there nothing that warrants a positive rns? If you cannot apply the time required then move on and let someone else take control, this should be motoring now but is left to languish...what a travesty!
Afternoon folks, been away from the B.B. for Few days in the hope that a corner may be turned, result .... zilch! Pretty much back where I left it. On the positive side there has been a bit more buying trade and as Botak, El say FDBK are sitting at the right tables. So why do the beloved mms insist on depressing the sp? If Tobriand is right then a really positive rns could come out of nowhere from a research project begun a couple of years ago. But many AIM coys with nothing like the credibility of TexRAD behind them would be flying just on the potential returns afforded yet the market chooses to ignore the provenance of FDBK which imo is now quite undervalued. Frustrated and I simply don’t get it, we could be waiting another 2 years for strong revenue flow to force a rerating....crazy!
Isn�t it strange how the CE was going to send the sp into orbit, but instead we have zilch. What�s your take on the volume and buy/sell ratios El? I just cannot understand what the market needs now to get this moving. Far too small to attract the institutions but what is the BOD game plan? Hors, IF, Botak and others with substantial commitment here what are your thoughts?
It would be very interesting to help with diagnosis of this terrible disease but bear in mind AR said Liver might be next for CE in appx 6 months, so not sure where Prostrate would fit in FDBK plans with the limited resources available. Priority for now must be to get to profitability and secure sales for Lung and get it into as many regions as possible. Expecting a LOT of good news come the Feb results..
Thanks El, brings me up to date. With many AIM tech stocks the market is happy to rate on potential growth when there is a market leading story ie IQE, Versarien but FDBK never seems to get the credit for its huge potential in its sp. if just the NHS take this on it will be huge but we also have the Far East, India etc, and then there is Liver in appx 6 months as well as others to follow...none of which is in the rating. Guess I�ve talked myself into a top up next week, at these ridiculously low sps! Night all, take care...
Evening Hors, Bo, maybe I am being a little naive but if TexRAD can be integrated into NHS scanners for Lung diagnosis an in so doing save time and money as well as speeding up a clearer diagnosis then why is the sp still in the doldrums? This should be an off the chart money spinner. Enjoy your weekend.
Evening Botak, that is a stunning statistic. I�m not sure how much of an impact TexRAD can have if it is a question of manpower but the fact that diagnosis could be quicker and more accurate should be helpful. Trouble is will anyone at FDBK tell the NHS? Another week draws to a close and even the longed for CE still has not impacted. I said I would be here for the longterm and that is my aim but I would like to be alive long enough to reap some benefit from my investment, so an advance towards the 5p of old would be most welcome. Have a good weekend all....
Hi folks, interesting that the Alliance trial is now underway does anyone know or have a feel for how long this will take before results are known. I am confident the results will be positive, after all it has been tested to death internationally but how soon will an rns be available? Could be the catalyst we have been waiting for, meantime a good buying opportunity for dedicated lths.
Your optimism is always refreshing Hors. Maybe it�s just me but I get the feeling that the BOD are very complacent and dismissive of shareholder concerns. There should be a statement following the AGM to outline plans for this year and there should be accountability, but I�m not holding my breath. Be very good to hear your balanced thoughts following the AGM.
Morning folks, what is your take on this mornings trades El? Looks like some might be buys and the sp has ticked up a bit. Do you think there will be a big bounce back to 3-3.5 sometime or just tiny increments? Hard to see what will cause a seismic shift atm.